Abstract
Withania somnifera (WS) plant has been used for centuries to cure or treat various disorders in the Ayurvedic medicine. Research over the years has indicated that withanolides are the primary bioactive constituents in WS. Scientific evidence for anticancer effects of WS root extract (WRE) is quite strong, and is derived from both in vitro cellular experiments and in vivo studies in rodent models of cancer. This article reviews scientific evidence supporting anticancer effects of WRE and its primary withanolide (withaferin A). The primary focus of the present article is on: (a) phytochemistry of WS, (b) withanolide biosynthesis, (c) pharmacokinetics, (d) in vivo evidence for anticancer activity of WRE and its primary bioactive component withaferin A (WA), and (e) effect of WA and WRE on cancer stem cell population and/or epithelial-mesenchymal transition. Unpublished results from our own laboratory are presented to demonstrate that WA is the most likely primary anticancer agent in WRE standardized for WA content (sWRE). The mechanisms underlying anticancer effects of WRE and WA have been reviewed extensively by us and others, and therefore are not elaborated in this article.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
